Giuseppe La Regina

Pubblicazioni

Titolo Pubblicato in Anno
CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme EUROPEAN JOURNAL OF PHARMACOLOGY 2021
RS4651 suppresses lung fibroblast activation via the TGF-β1/SMAD signalling pathway EUROPEAN JOURNAL OF PHARMACOLOGY 2021
RS-5645 attenuates inflammatory cytokine storm induced by SARS-CoV-2 spike protein and LPS by modulating pulmonary microbiota INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES 2021
Targeting PDZ domains as potential treatment for viral infections, neurodegeneration and cancer BIOLOGY DIRECT 2021
Discovery of a novel class of norovirus inhibitors with high barrier of resistance PHARMACEUTICALS 2021
Emerging therapeutic agents for colorectal cancer MOLECULES 2021
Selenotriapine - an isostere of the most studied thiosemicarbazone with pronounced pro-apoptotic activity, low toxicity and ability to challenge phenotype reprogramming of 3-D mammary adenocarcinoma tumors ARABIAN JOURNAL OF CHEMISTRY 2020
Discovery of new 1,1'-biphenyl-4-sulfonamides as selective subnanomolar human carbonic anhydrase II inhibitors ACS MEDICINAL CHEMISTRY LETTERS 2020
Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2020
Discovery of Zika virus NS2B/NS3 inhibitors that prevent mice from fife-threatening infection and brain damage ACS MEDICINAL CHEMISTRY LETTERS 2020
New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2020
Sulfonamide inhibitors of beta-Catenin signaling as anticancerAgents with different output on c-Myc CHEMMEDCHEM 2020
Targeting the interaction between the SH3 domain of Grb2 and Gab2 CELLS 2020
A new case manager for diabetic patients: a pilot observational study of the role of community pharmacists and pharmacy services in the case management of diabetic patients PHARMACY 2020
Drug design and synthesis of first in class PDZ1 targeting NHERF1 inhibitors as anticancer agents ACS MEDICINAL CHEMISTRY LETTERS 2019
Towards modern anticancer agents that interact with tubulin EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 2019
Small molecule inhibitors of KDM5 histone demethylases increase the radiosensitivity of breast cancer cells overexpressing Jarid1b MOLECULES 2019
Switching on the activity of 1,5-diaryl-pyrrole derivatives against drug-resistant ESKAPE bacteria: structure-activity relationships and mode of action studies EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2019
Bax activation blocks self-renewal and induces apoptosis of human glioblastoma stem cells ACS CHEMICAL NEUROSCIENCE 2018
A negative allosteric modulator of WNT receptor frizzled 4 switches into an allosteric agonist BIOCHEMISTRY 2018

ERC

  • LS1_13
  • PE5_17
  • PE5_18

KET

  • Life-science technologies & biotechnologies

Interessi di ricerca

Progettazione, sintesi e sviluppo di agenti anti-infettivi (HIV-1, Rhinovirus, virus dell’epatite C, virus Dengue, Mycobacterium tuberculosis, Candida albicans), anti-tumorali (tubulina, apoptosi, istone demetilasi, metalloproteinasi di matrice, membri della famiglia BCL-2, Frizzled4, anidrasi carbonica, indolamina 2,3-diossigenasi 1, MDM2/MDM4, NHERF1, beta-catenina) e attivi sul sistema nervoso centrale (monoammino ossidasi, sistema endocannabinoide, glicogeno sintasi chinasi 3 beta); sintesi microonde-assistita; studi di modellistica molecolare.

Keywords

drug design and discovery
Anti-Infective Agents
anticancer agent

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma